Tag Archives: Alan Carr

Needham Sticks to Its Buy Rating for Zealand Pharma A/S (ZEAL)

In a report released today, Alan Carr from Needham maintained a Buy rating on Zealand Pharma A/S (ZEAL – Research Report), with a price target of $29. The company’s shares opened today at $14.60. Carr said: “Zealand mgmt hosted a

Moderna Inc (MRNA) Received its Third Buy in a Row

After Piper Jaffray and Oppenheimer gave Moderna Inc (NASDAQ: MRNA) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr maintained a Buy rating on Moderna Inc today and set a price target

Needham Maintains a Buy Rating on Alnylam Pharma (ALNY)

In a report released today, Alan Carr from Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $135. The company’s shares opened today at $82.34. Carr said: “Alnylam reported $12.1M in 4Q18

Needham Downgrades Neurocrine (NBIX) to Hold

Needham analyst Alan Carr downgraded Neurocrine (NBIX – Research Report) to Hold today. The company’s shares closed yesterday at $89.32. According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.8% and a 41.7% success rate. Carr

Albireo Pharma Inc (ALBO) Receives a Buy from Needham

Needham analyst Alan Carr maintained a Buy rating on Albireo Pharma Inc (ALBO – Research Report) today and set a price target of $50. The company’s shares opened today at $24.94. Carr observed: “Albireo provided a quarterly corporate update today

Neurocrine (NBIX) Receives a Buy from Needham

In a report released today, Alan Carr from Needham maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $125. The company’s shares opened today at $106.56. Carr noted: “Neurocrine reported $111.3M in 3Q18 Ingrezza